MAO-B-IN-37, identified by its CAS number 894280-02-5, is a selective inhibitor of the enzyme monoamine oxidase B (MAO-B). This enzyme is involved in the breakdown of neurotransmitters such as dopamine, and its inhibition can have significant implications for neurological health, particularly in the context of neurodegenerative diseases like Parkinson's disease. MAO-B inhibitors are known to enhance dopaminergic activity, potentially alleviating symptoms associated with dopamine deficiency. The compound is characterized by its ability to selectively bind to the MAO-B enzyme, thereby reducing its activity without significantly affecting MAO-A, which is responsible for the metabolism of other neurotransmitters. This selectivity is crucial for minimizing side effects and maximizing therapeutic benefits. Additionally, MAO-B-IN-37 may exhibit favorable pharmacokinetic properties, such as good oral bioavailability and a suitable half-life, making it a candidate for further research and development in the treatment of conditions related to dopaminergic dysfunction. However, detailed studies on its efficacy, safety, and mechanism of action are essential for a comprehensive understanding of its potential applications.

MAO-B-IN-37

894280-02-5: MAO-B-IN-37, identified by its CAS number 894280-02-5, is a selective inhibitor of the enzyme monoamine oxidase B (MAO-B). This enzyme is involved in the breakdown of neurotransmitters such as dopamine, and its inhibition can have significant implications for neurological health, particularly in the context of neurodegenerative diseases like Parkinson's disease. MAO-B inhibitors are known to enhance dopaminergic activity, potentially alleviating symptoms associated with dopamine deficiency. The compound is characterized by its ability to selectively bind to the MAO-B enzyme, thereby reducing its activity without significantly affecting MAO-A, which is responsible for the metabolism of other neurotransmitters. This selectivity is crucial for minimizing side effects and maximizing therapeutic benefits. Additionally, MAO-B-IN-37 may exhibit favorable pharmacokinetic properties, such as good oral bioavailability and a suitable half-life, making it a candidate for further research and development in the treatment of conditions related to dopaminergic dysfunction. However, detailed studies on its efficacy, safety, and mechanism of action are essential for a comprehensive understanding of its potential applications.

<p>MAO-B-IN-37 (Compound 37) is a derivative of TT01001 and acts as a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 270 nM. It exhibits good metabolic stability in mouse microsomes and shows strong affinity for human serum albumin.</p>

CAS 894280-02-5

MAO-B-IN-37

MAO-B-IN-37

Ref: TM-T203156